Karyopharm (KPTI) Reports Q1 2025 Earnings with Revenue Decline and Guidance Update
Karyopharm (KPTI) reported Q1 2025 revenue of $30 million, a decrease from $33.1 million in the same period in 2024, primarily due to increased product return provisions. The company also provided guidance for total revenue of $140 million to $155 million, with management expecting performance towards the lower end of the range.
Tickers: $KPTI
Topics: earnings financial performance guidance product returns R&D expenses revenue